| http://purl.uniprot.org/citations/34465596 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/34465596 | http://www.w3.org/2000/01/rdf-schema#comment | "A fundamental understanding of cancer-specific antigens is crucial for successful T-cell immunotherapy. Sarcoma antigen 1 (SAGE1) is a cancer/testis antigen that has not yet been verified for T-cell immunotherapy applications. Here, we examined SAGE1 RNA expression and carried out IHC analyses, revealing that SAGE1 is expressed in 50% of non-small cell lung-cancer samples (n = 40). To verify the immunogenicity of SAGE1, we discovered a novel HLA-A*24:02 (HLA-A24)-restricted SAGE1 epitope (SAGE1597-606, VFSTAPPAFI) using mass spectrometry and identified SAGE1597-606-specific T-cell clones and T-cell receptors (TCR) from peripheral bloods of HLA-A24+ donors. The highest affinity TCR VF3 (KD = 4.3 μM) demonstrated the highest antitumor potency. Moreover, VF3-transduced T cells mediated the efficient killing of HLA-A24+/SAGE1+ tumor cells in vitro and effectively inhibited the growth of lung cancer xenografts in mice. Together, our data suggest that SAGE1 could be a target for T-cell immunotherapies against lung cancer, while its specific TCRs could be candidates for developing reagents to treat SAGE1+ tumors."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.org/dc/terms/identifier | "doi:10.1158/1535-7163.mct-21-0203"xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Gong H."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Liu Q."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Li Y."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Zhang Y."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Yu X."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Zheng H."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Zhong S."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/author | "Chen A.A."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/name | "Mol Cancer Ther"xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/pages | "2302-2313"xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/title | "SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy."xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://purl.uniprot.org/core/volume | "20"xsd:string |
| http://purl.uniprot.org/citations/34465596 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/34465596 |
| http://purl.uniprot.org/citations/34465596 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/34465596 |
| http://purl.uniprot.org/uniprot/#_B7ZM42-mappedCitation-34465596 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/34465596 |
| http://purl.uniprot.org/uniprot/#_Q9NXZ1-mappedCitation-34465596 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/34465596 |
| http://purl.uniprot.org/uniprot/Q9NXZ1 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/34465596 |
| http://purl.uniprot.org/uniprot/B7ZM42 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/34465596 |